Abstract
Objectives: To measure older adults acceptability of dementia screening and assess screening test results of a racially diverse sample of older primary care patients in the United States.
Design: Cross-sectional study of primary care patients aged 65 and older.
Setting: Urban and suburban primary care clinics in Indianapolis, Indiana, in 2008 to 2009.
Participants: Nine hundred fifty-four primary care patients without a documented diagnosis of dementia.
Measurements: Community Screening Instrument for Dementia, the Mini-Mental State Examination, and the Telephone Instrument for Cognitive Screening.
Results: Of the 954 study participants who consented to participate, 748 agreed to be screened for dementia and 206 refused screening. The overall response rate was 78.4%. The positive screen rate of the sample who agreed to screening was 10.2%. After adjusting for demographic differences the following characteristics were still associated with increased likelihood of screening positive for dementia: age, male sex, and lower education. Patients who believed that they had more memory problems than other people of their age were also more likely to screen positive for dementia.
Conclusion: Age and perceived problems with memory are associated with screening positive for dementia in primary care.
Keywords: Dementia screening, Alzheimer's disease, primary care, diagnostic assessment, memory.
Current Alzheimer Research
Title:Acceptability and Results of Dementia Screening Among Older Adults in the United States
Volume: 15 Issue: 1
Author(s): Amanda Harrawood, Nicole R. Fowler*, Anthony J. Perkins, Michael A. LaMantia and Malaz A. Boustani
Affiliation:
- Department of Medicine, Indiana University, Center for Aging Research, Indianapolis, IN 46202,United States
Keywords: Dementia screening, Alzheimer's disease, primary care, diagnostic assessment, memory.
Abstract: Objectives: To measure older adults acceptability of dementia screening and assess screening test results of a racially diverse sample of older primary care patients in the United States.
Design: Cross-sectional study of primary care patients aged 65 and older.
Setting: Urban and suburban primary care clinics in Indianapolis, Indiana, in 2008 to 2009.
Participants: Nine hundred fifty-four primary care patients without a documented diagnosis of dementia.
Measurements: Community Screening Instrument for Dementia, the Mini-Mental State Examination, and the Telephone Instrument for Cognitive Screening.
Results: Of the 954 study participants who consented to participate, 748 agreed to be screened for dementia and 206 refused screening. The overall response rate was 78.4%. The positive screen rate of the sample who agreed to screening was 10.2%. After adjusting for demographic differences the following characteristics were still associated with increased likelihood of screening positive for dementia: age, male sex, and lower education. Patients who believed that they had more memory problems than other people of their age were also more likely to screen positive for dementia.
Conclusion: Age and perceived problems with memory are associated with screening positive for dementia in primary care.
Export Options
About this article
Cite this article as:
Harrawood Amanda, Fowler R. Nicole *, Perkins J. Anthony , LaMantia A. Michael and Boustani A. Malaz , Acceptability and Results of Dementia Screening Among Older Adults in the United States, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908100905
DOI https://dx.doi.org/10.2174/1567205014666170908100905 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Pharmacological Management of Acutely Agitated Schizophrenic Patients
Current Pharmaceutical Design Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Multipotent, Permeable Drug ASS234 Inhibits Aβ Aggregation, Possesses Antioxidant Properties and Protects from Aβ-induced Apoptosis In Vitro
Current Alzheimer Research Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Pleiotropic Effects of Statins in Atherosclerotic Disease: Focus on the Antioxidant Activity of Atorvastatin
Current Topics in Medicinal Chemistry Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued) Comparative Effectiveness of Agmatine and Choline Treatment in Rats with Cognitive Impairment Induced by AlCl<sub>3</sub> and Forced Swim Stress
Current Clinical Pharmacology Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?
Current Medicinal Chemistry Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design